OR Stock Analysis: LOréal S.A. | PA
Household & Personal Products | PA, France | Market Cap: 203.030m EUR | 12M Return: 5.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 119M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LOréal S.A. is a French-headquartered global cosmetics manufacturer operating through four reporting divisions: Professional Products, Consumer Products, Luxe, and Dermatological Beauty. Its product portfolio spans skincare, make-up, hair colourants, haircare, perfume, and hygiene, sold under a large house-of-brands strategy that ranges from mass-market labels such as LOréal Paris, Garnier, and Maybelline New York to prestige and luxury lines such as Lancôme, Yves Saint Laurent Beauté, Kiehls, and Aesop, plus dermatologist-positioned brands including La Roche-Posay, CeraVe, and Vichy. Founded in 1909 and listed in Paris, the group sells across virtually every major region, from Europe and North America to Asia-Pacific, the Middle East, Africa, and Latin America.
The company sits in the Consumer Staples sector, Personal Care Products sub-industry, and earns revenue through a highly diversified multi-channel distribution model covering hair salons, pharmacies and drugstores, mass-market retail, department store perfumeries, free-standing stores, travel retail, and e-commerce, allowing it to serve consumers across price tiers and category entry points. This combination of a broad brand portfolio spanning mass to luxury, a presence across professional, retail, and digital channels, and globally balanced geographic exposure is characteristic of large-scale personal care players.
- North Asia luxury demand weakness pressures Luxe division growth
- Dermatological Beauty segment drives margin expansion via CeraVe and La Roche-Posay
- Travel retail recovery remains uncertain amid Chinese consumer caution
| Net Income: 10.3b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA 10.54 > 1.0 |
| NWC/Revenue: 8.96% < 20% (prev 2.21%; Δ 6.75% < -1%) |
| CFO/TA 0.27 > 3% & CFO 16.9b > Net Income 10.3b |
| Net Debt (8.73b) to EBITDA (18.2b): 0.48 < 3 |
| Current Ratio: 1.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (535.8m) vs 12m ago -0.21% < -2% |
| Gross Margin: 74.89% > 18% (prev 75.31%; Δ -0.42% > 0.5%) |
| Asset Turnover: 129.0% > 50% (prev 147.6%; Δ -18.61% > 0%) |
| Interest Coverage Ratio: 26.39 > 6 (EBIT TTM 15.0b / Interest Expense TTM 567.1m) |
| A: 0.11 (Total Current Assets 22.2b - Total Current Liabilities 15.4b) / Total Assets 61.8b |
| B: 0.39 (Retained Earnings 24.3b / Total Assets 61.8b) |
| C: 0.25 (EBIT TTM 15.0b / Avg Total Assets 59.1b) |
| D: 1.30 (Book Value of Equity 35.0b / Total Liabilities 26.8b) |
| Altman-Z'' = 5.08 = AAA |
| DSRI: 1.12 (Receivables 5.73b/5.60b, Revenue 76.2b/83.2b) |
| GMI: 1.01 (GM 75.31% / 74.89%) |
| AQI: 0.91 (AQ_t 0.55 / AQ_t-1 0.60) |
| SGI: 0.92 (Revenue 76.2b / 83.2b) |
| TATA: -0.11 (NI 10.3b - CFO 16.9b) / TA 61.8b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of July 23, 2026, the stock is trading at EUR 380.65 with a total of 273,111 shares traded. Over the past week, the price has changed by +0.54%, over one month by +0.67%, over three months by +12.53% and over the past year by +5.48%.
Current recommended Stop Loss: 367.10 (which is 3.6% or 1.8 ATR below the current price).
LOréal S.A. has no consensus analysts rating.
P/E Trailing = 33.364
P/E Forward = 27.7778
P/S = 4.6137
P/B = 5.8086
P/EG = 2.525
Revenue TTM = 76.2b EUR
EBIT TTM = 15.0b EUR
EBITDA TTM = 18.2b EUR
Long Term Debt = 8.07b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.48b EUR (from shortTermDebt, last quarter)
Debt = 13.7b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.80b
Net Debt = 8.73b EUR (calculated: Debt 13.7b - CCE 4.99b)
Enterprise Value = 212b EUR (203b + Debt 13.7b - CCE 4.99b)
Interest Coverage Ratio = 26.39 (Ebit TTM 15.0b / Interest Expense TTM 567.1m)
EV/FCF = 15.34x (Enterprise Value 212b / FCF TTM 13.8b)
FCF Yield = 6.52% (FCF TTM 13.8b / Enterprise Value 212b)
FCF Margin = 18.11% (FCF TTM 13.8b / Revenue TTM 76.2b)
Net Margin = 13.53% (Net Income TTM 10.3b / Revenue TTM 76.2b)
Gross Margin = 74.89% ((Revenue TTM 76.2b - Cost of Revenue TTM 19.1b) / Revenue TTM)
Gross Margin QoQ = 78.70% (prev 74.67%)
Tobins Q-Ratio = 3.43 (Enterprise Value 212b / Total Assets 61.8b)
Interest Expense / Debt = 4.14% (Interest Expense 567.1m / Debt 13.7b)
Taxrate = 26.59% (3.72b / 14.0b)
NOPAT = 11.0b (EBIT 15.0b * (1 - 26.59%))
Current Ratio = 1.44 (Total Current Assets 22.2b / Total Current Liabilities 15.4b)
Debt / Equity = 0.39 (Debt 13.7b / totalStockholderEquity, last quarter 35.0b)
Debt / EBITDA = 0.48 (Net Debt 8.73b / EBITDA 18.2b)
Debt / FCF = 0.63 (Net Debt 8.73b / FCF TTM 13.8b)
Total Stockholder Equity = 32.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.46% (Net Income 10.3b / Total Assets 61.8b)
RoE = 32.01% (Net Income TTM 10.3b / Total Stockholder Equity 32.2b)
RoCE = 37.14% (EBIT 15.0b / Capital Employed (Equity 32.2b + L.T.Debt 8.07b))
RoIC = 24.34% (NOPAT 11.0b / Invested Capital 45.1b)
WACC = 6.14% (E(203b)/V(217b) * Re(6.35%) + D(13.7b)/V(217b) * Rd(4.14%) * (1-Tc(0.27)))
Discount Rate = 6.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -0.81 | Cagr: -1.93%
[DCF] Terminal Value 77.97% ; FCFF base≈10.9b ; Y1≈12.5b ; Y5≈18.5b
[DCF] Fair Price = 505.4 (EV 278b - Net Debt 8.73b = Equity 269b / Shares 532.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -63.47 | EPS CAGR: -2.38% | SUE: N/A | # QB: 0
Revenue Correlation: -26.97 | Revenue CAGR: -3.99% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=13.68 | Chg30d=+0.30% | Revisions=+42% | GrowthEPS=+7.6% | GrowthRev=+5.5%
EPS next Year (2027-12-31): EPS=14.84 | Chg30d=+0.52% | Revisions=+42% | GrowthEPS=+8.5% | GrowthRev=+6.0%
[Analyst] Revisions Ratio: +48% (up=14, down=4)